STAT Plus: Pharmalittle: Combining antibiotics may cause resistance; Lilly moves into dermatitis market with $1.1 billion deal

STAT Plus: Pharmalittle: Combining antibiotics may cause resistance; Lilly moves into dermatitis market with $1.1 billion deal

January 10, 2020 Alex Hogan/STAT A nd so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is modest and also abbreviated, since we will eventually make our way to a celebrated, if overcrowded, event starting early next week where biopharma and finance folks huddle and hondel. But what about you? If you are heading to the same destination, well, we hope you have an easy trip. As for the rest of you, this may be a good time to catch up on sundry errands, that growing reading list, or reaching out to someone special. Or maybe a few long naps are in order. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon. Combining multiple antibiotics may make bacteria more likely to develop resistance , Scientific American writes. A new study suggests that drug combinations can actually speed the development of resistance, and although small, the study reveals a major threat to the way doctors currently think about combination antibiotics. “Our entire approach to antibiotics is going to have to be rethought,” said Ramanan Laxminarayan, director of the Center for Disease Dynamics, Economics and Policy in Washington, D.C., who was not involved in the work. Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months! Log In | Learn More What is it? STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. What's included? The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day Online intelligence briefings Frequent opportunities to engage with veteran beat reporters and industry experts Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more



Also in Industry News

How to decide whether or not to start treatment for prostate cancer?
How to decide whether or not to start treatment for prostate cancer?

0 Comments

How to decide whether or not to start treatment for prostate cancer?

Read More

Analysis of the SARS-CoV-2 proteome via visual tools
Analysis of the SARS-CoV-2 proteome via visual tools

0 Comments

Analysis of the SARS-CoV-2 proteome via visual tools

Read More

$65m investment increases British Patient Capital’s exposure to life sciences and health technology
$65m investment increases British Patient Capital’s exposure to life sciences and health technology

0 Comments

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

Read More